CTOs on the Move

TechLab

www.techlab.com

 
TechLab is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.techlab.com
  • 2001 Kraft Dr
    Blacksburg, VA USA 24060
  • Phone: 540.953.1664

Executives

Name Title Contact Details

Similar Companies

Standard Bariatrics

Cincinnati-based surgical procedure company focused on innovative development, commercialization of medical devices for treatment of obesity, gastrectomy.

Gemini Therapeutics

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.

Independent Living Inc. Pediatric Therapy Tampa FL

FREE developmental screening! Tampa, St. Petersburg, Wesley Chapel clinic and school based pediatric therapy services. Physical, Occupational, Speech, Applied Behavioral Analysis

Lakemary

Founded in 1969, Lakemary is in America’s Heartland. Our main campus and ranch are on 32 acres in the quiet town of Paola, KS just south of Kansas City. Our...

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).